BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P26
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -6.93% |
| Q3 2025 | 2.03% |
| Q2 2025 | 16.41% |
| Q1 2025 | -24.62% |
| Q4 2024 | 20.35% |
| Q3 2024 | 9.19% |
| Q2 2024 | -19.08% |
| Q1 2024 | -33.63% |
| Q4 2023 | 49.43% |
| Q3 2023 | -8.52% |
| Q2 2023 | 5.91% |
| Q1 2023 | -33.90% |
| Q4 2022 | 38.81% |
| Q3 2022 | -14.92% |
| Q2 2022 | -5.16% |
| Q1 2022 | 2.88% |
| Q4 2021 | 27.13% |
| Q3 2021 | -5.49% |
| Q2 2021 | 24.60% |
| Q1 2021 | 20.03% |
| Q4 2020 | 16.89% |
| Q3 2020 | 9.99% |
| Q2 2020 | -7.93% |
| Q1 2020 | 11.55% |
| Q4 2019 | 6.58% |
| Q3 2019 | -9.25% |
| Q2 2019 | 0.68% |
| Q1 2019 | 17.34% |
| Q4 2018 | 6.48% |
| Q3 2018 | 4.74% |
| Q2 2018 | 13.93% |
| Q1 2018 | 8.96% |
| Q4 2017 | -3.34% |
| Q3 2017 | 11.10% |
| Q2 2017 | -6.03% |
| Q1 2017 | 37.93% |
| Q4 2016 | -13.80% |
| Q3 2016 | -0.43% |
| Q2 2016 | -31.16% |
| Q1 2016 | 8.04% |